Glioblastoma Multiforme (GBM) Treatment Market Report 2026

Glioblastoma Multiforme (GBM) Treatment Market Overview

• Glioblastoma Multiforme (GBM) Treatment market size has reached to $2.73 billion in 2025 • Expected to grow to $4.46 billion in 2030 at a compound annual growth rate (CAGR) of 10.2% • Growth Driver: Rising Cases Of Brain Disorder • Market Trend: Innovative Devices Enhancing Glioblastoma Multiforme Treatment Landscape • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Glioblastoma Multiforme (GBM) Treatment Market?

Glioblastoma multiforme (GBM) treatment refers to the management and care of a patient suffering from glioblastoma multiforme, a kind of brain or spinal cord tumor that grows quickly. Adults with this primary malignant brain tumor have the highest prevalence rate. The main treatment of glioblastoma multiforme (GBM) treatment are surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field (TTF) therapy, and immunotherapy. Surgery is a field of medicine that focuses on using manual and instrumental methods to heal wounds, illnesses, and other ailments. The drugs types involved are emozolomide, bevacizumab, lomustine, carmustine wafers, and others that are administered by oral, parenteral, other routes of administration and used by hospitals, clinics, ambulatory surgical centers.

What Is The Glioblastoma Multiforme (GBM) Treatment Market Growth Forecast?

The glioblastoma multiforme (gbm) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.46 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to development of targeted therapies, expansion of immunotherapy pipelines, precision medicine adoption, increased clinical trial activity, rising research funding. Major trends in the forecast period include rising adoption of multimodal treatment regimens, increased use of tumor treating field therapy, growing focus on personalized gbm therapies, expansion of immunotherapy approaches, improved post-surgical treatment protocols.

Global Glioblastoma Multiforme (GBM) Treatment Market Segmentation

1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, R Immunotherapy 2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations 4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers Subsegments: 1) By Surgery: Tumor Resection, Biopsy Procedures 2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy 3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens 4) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies

What Is The Driver Of The Glioblastoma Multiforme (GBM) Treatment Market?

The increasing prevalence of brain disorders is expected to propel the growth of the glioblastoma multiforme (GBM) treatment market going forward. Brain disorders refer to abnormal functioning of the brain as well as the nerves found throughout the human body and the spinal cord. The increasing prevalence of brain disorders such as glioblastoma multiforme (GBM) is due to various contributing factors such as the aging population, compromised immune systems, overdiagnosis, ionizing radiation, air pollution, and others which creates the need for the treatment of brain disorders to improve well-being. For instance, in February 2025, according to Dementia Australia, an Australia-based non-profit organization, approximately 433,300 Australians are living with dementia, with this number expected to rise to 812,500 by 2054. Additionally, younger-onset dementia affects around 29,000 people in 2025, with projections indicating an increase to 41,000 by 2054. Therefore, the increasing prevalence of brain disorders is driving the growth of the glioblastoma multiforme (GBM) treatment industry.

Key Players In The Global Glioblastoma Multiforme (GBM) Treatment Market

Major companies operating in the glioblastoma multiforme (gbm) treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, Loxo Oncology Inc., Karyopharm Therapeutics Inc., EnGeneIC Ltd., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc

Global Glioblastoma Multiforme (GBM) Treatment Market Trends and Insights

Major companies operating in the market are focused on development of innovative wearable and portable devices to sustain their position in the market. These advancements aim to offer users enhanced functionality, convenience, and comfort, catering to the growing demand for accessible and efficient healthcare solutions. For instance, in 2023, Novocure, a Jersey-based oncology company, launched Optune Gio, a wearable and portable treatment system for patients with newly diagnosed glioblastoma (GBM), approved by the FDA. This device employs Tumor Treating Fields (TTFields), which are alternating electric fields that disrupt cancer cell division, potentially extending patient survival. Weighing only 2.7 pounds, Optune Gio is designed for comfort, allowing patients to wear it during daily activities.

What Are Latest Mergers And Acquisitions In The Glioblastoma Multiforme (GBM) Treatment Market?

In October 2024, Merck & Co., a US-based pharmaceutical company specializing in prescription medicines and vaccines, acquired Modifi Biosciences for an undisclosed amount. Through this acquisition, Merck aims to advance its oncology pipeline by integrating Modifi’s preclinical small-molecule platform, which targets cancer cells with defects in deoxyribonucleic acid (DNA) repair, including those lacking the O6-methylguanine-DNA methyltransferase (MGMT) protein, and shows potential against highly refractory tumors such as glioblastoma. Modifi Biosciences Inc. is a US-based company that provides a treatment targeting Glioblastoma Multiforme (GBM).

Regional Outlook

North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Glioblastoma Multiforme (GBM) Treatment Market?

The glioblastoma multiforme (GBM) treatment market includes revenues earned by entities by performing neurological exams, imaging tests, surgical operations, radiotherapy, and molecular profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glioblastoma Multiforme (GBM) Treatment Market Report 2026?

The glioblastoma multiforme (gbm) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glioblastoma multiforme (gbm) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.